Haleon (NYSE:HLN) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Haleon from “Buy” to “Hold,” while the broader analyst consensus remains “Moderate Buy.” Ratings include two Strong Buys, two Buys, four Holds and one Sell.
• Haleon shares opened at $8.79, near their one-year low of $8.65 and below the 50-day and 200-day moving averages of $9.65 and $9.55, respectively.
• Institutional investors increased their holdings, including Arrowstreet Capital, Bank of America and Goldman Sachs; institutions and hedge funds collectively own 6.67% of Haleon.

Haleon (NYSE:HLN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Royal Bank Of Canada reissued a "sector perform" rating on shares of Haleon in a research report on Tuesday, August 11th. Rothschild & Co Redburn downgraded Haleon from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 16th. Jefferies Financial Group restated a "buy" rating on shares of Haleon in a research report on Wednesday, September 23rd. Zacks Research upgraded Haleon from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Haleon in a report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy".

Haleon Price Performance

HLN stock opened at $8.79 on Friday. The firm has a market capitalization of $38.68 billion, a P/E ratio of 22.55, a P/E/G ratio of 1.97 and a beta of 0.14. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. The business's 50-day moving average is $9.65 and its two-hundred day moving average is $9.55. Haleon has a 1 year low of $8.65 and a 1 year high of $11.28.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership lifted its holdings in Haleon by 82.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company's stock worth $146,892,000 after buying an additional 6,647,329 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Haleon by 17.0% in the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock valued at $109,452,000 after purchasing an additional 1,586,230 shares during the period. Sculptor Capital LP boosted its position in shares of Haleon by 5.1% during the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company's stock worth $105,699,000 after buying an additional 505,000 shares during the period. Goldman Sachs Group Inc. increased its position in Haleon by 18.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,441,178 shares of the company's stock valued at $105,560,000 after acquiring an additional 1,589,494 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in Haleon by 0.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 5,397,200 shares of the company's stock worth $54,566,000 after acquiring an additional 13,651 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.